SCHEMBL19617451

SCHEMBL19617451

CC(C)c1cc(Cc2c(Cl)cc(OCC(=O)O)cc2Cl)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 19/20 1.00
THRA P10827 18/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30762937 0.95 THRB (0.91) THRBTHRA
SCHEMBL22106256 0.95 THRB (0.91) THRBTHRA
SCHEMBL30763153 0.93 THRB (0.87) THRBTHRA
SCHEMBL22100229 0.93 THRB (0.87) THRBTHRA
SCHEMBL22106076 0.92 THRB (0.85) THRBTHRA
SCHEMBL30763059 0.92 THRB (0.85) THRBTHRA
SCHEMBL29977021 0.91 THRB (0.83) THRBTHRA
SCHEMBL22106066 0.90 THRB (0.80) THRBTHRA
SCHEMBL22106080 0.90 THRB (0.80) THRBTHRA
SCHEMBL30762989 0.90 THRB (0.80) THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425437-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2024-12-26 US disclosed
EP-4333844-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS Autobahn Therapeutics, Inc. (US) 2024-03-13 EP disclosed
CN-117597122-A Fatty Acid Amide Hydrolase (FAAH) cleavable prodrugs of thyromimetics and combinations with peripherally restricted FAAH inhibitors 速通医疗公司 2024-02-23 CN disclosed
US-20230348364-A1 ISOTOPIC THYROMIMETIC COMPOUNDS AUTOBAHN THERAPEUTICS, INC. 2023-11-02 US disclosed
US-20230348364-A1 ISOTOPIC THYROMIMETIC COMPOUNDS AUTOBAHN THERAPEUTICS, INC. 2023-11-02 US disclosed
US-20230348364-A1 ISOTOPIC THYROMIMETIC COMPOUNDS AUTOBAHN THERAPEUTICS, INC. 2023-11-02 US disclosed
US-20230048992-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-02-16 US disclosed
US-11578032-B2 Derivatives of sobetirome OREGON HEALTH & SCIENCE UNIVERSITY (US) 2023-02-14 US disclosed
WO-2022236133-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS AUTOBAHN THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
WO-2022236133-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS AUTOBAHN THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
US-20210002208-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2021-01-07 US disclosed
US-10870616-B2 Derivatives of sobetirome OREGON HEALTH & SCIENCE UNIVERSITY (US) 2020-12-22 US disclosed
US-10870616-B2 Derivatives of sobetirome OREGON HEALTH & SCIENCE UNIVERSITY (US) 2020-12-22 US disclosed
US-20200325092-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2020-10-15 US disclosed
US-20200325092-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2020-10-15 US disclosed
US-10544075-B2 Derivatives of sobetirome OREGON HEALTH & SCIENCE UNIVERSITY (US) 2020-01-28 US disclosed
WO-2019160980-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2019-08-22 WO disclosed
US-20190210950-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2019-07-11 US disclosed
EP-3457851-A1 DERIVATIVES OF SOBETIROME Oregon Health & Science University (US) 2019-03-27 EP disclosed
WO-2017201320-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348364-A1 ISOTOPIC THYROMIMETIC COMPOUNDS TPO, THOP1, TSHR THRB 6/4885THRA 7/4885
US-10870616-B2 Derivatives of sobetirome SNCA, SLC6A3, SLC6A1 THRB 2754/4885THRA 2915/4885
US-20230048992-A1 NOVEL THYROMIMETICS TSHR, TPO, CHRM1 THRB 9/4885THRA 8/4885
US-20200325092-A1 DERIVATIVES OF SOBETIROME SNCA, SLC6A3, SLC6A1 THRB 2754/4885THRA 2915/4885
US-20210002208-A1 DERIVATIVES OF SOBETIROME SLC6A3, TPH1, SLC6A2 THRB 149/4885THRA 213/4885
US-20190210950-A1 DERIVATIVES OF SOBETIROME SNCA, SLC6A3, SLC6A1 THRB 2754/4885THRA 2915/4885
US-20240425437-A1 DERIVATIVES OF SOBETIROME SNCA, SLC6A3, SLC6A1 THRB 2754/4885THRA 2915/4885
US-10544075-B2 Derivatives of sobetirome SNCA, SLC6A3, SLC6A1 THRB 2754/4885THRA 2915/4885
US-11578032-B2 Derivatives of sobetirome SLC6A3, TPH1, SLC6A2 THRB 149/4885THRA 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.